Noriyuki Ishihara
Overview
Explore the profile of Noriyuki Ishihara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
65
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Onita T, Ishihara N, Yano T
Antibiotics (Basel)
. 2025 Jan;
14(1).
PMID: 39858377
Antimicrobial resistance (AMR) poses a critical global health threat, necessitating the optimal use of existing antibiotics. Pharmacokinetic/pharmacodynamic (PK/PD) principles provide a scientific framework for optimizing antimicrobial therapy, particularly to respond...
2.
Onita T, Nakamura K, Nishikawa G, Ishihara N, Tamaki H, Yano T, et al.
J Clin Pharmacol
. 2024 Aug;
PMID: 39183683
This study aimed to develop a prostatic pharmacokinetic model of ceftazidime and suggest more effective dosing strategy for the bacterial prostatitis, based on a site-specific pharmacokinetic and pharmacodynamic perspective. Subjects...
3.
Onita T, Ikawa K, Ishihara N, Tamaki H, Yano T, Naora K, et al.
Antibiotics (Basel)
. 2023 Feb;
12(2).
PMID: 36830214
This study aimed to assess the dosing regimens of ampicillin/sulbactam for pneumonia based on pulmonary pharmacokinetic (PK)/pharmacodynamic (PD) target attainment. Using the literature data, we developed pulmonary PK models and...
4.
Onita T, Ishihara N, Ikebuchi A, Yano T, Nishimura N, Tamaki H, et al.
J Clin Pharm Ther
. 2022 Jul;
47(12):2041-2048.
PMID: 35893441
What Is Known And Objective: Linezolid (LZD) may cause thrombocytopenia, which can result in discontinuation of treatment. In this study, the blood LZD trough concentration was estimated based on population...
5.
Pharmacodynamic Evaluation of Ampicillin-sulbactam in Pediatric Patients Using Plasma and Urine Data
Onita T, Ikawa K, Ishihara N, Tamaki H, Yano T, Naora K, et al.
Pediatr Infect Dis J
. 2022 Feb;
41(5):411-416.
PMID: 35195566
Background: We aimed to develop population pharmacokinetic (PK) models of ampicillin and sulbactam using pooled data analysis and to optimize dosing regimens of ampicillin-sulbactam (combination ratio of 2:1) in pediatric...
6.
Ishihara N
Yakugaku Zasshi
. 2021 Dec;
141(12):1289-1296.
PMID: 34853200
In recent years, antimicrobial resistance bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) have become a global problem. One of the countermeasures is to optimize the use of antimicrobial drugs, specifically...
7.
Onita T, Ishihara N, Yano T, Nishimura N, Tamaki H, Ikawa K, et al.
Yakugaku Zasshi
. 2021 Mar;
141(3):441-445.
PMID: 33642514
Herein, we describe a case of an elderly patient with muscular dystrophy for whom control of the plasma vancomycin (VCM) concentration proved difficult when he developed a catheter-related bloodstream infection....
8.
Hotta T, Tsubata Y, Hamai K, Tanino A, Kobayashi M, Nakamura A, et al.
Respir Investig
. 2021 Jan;
59(3):327-334.
PMID: 33386292
Background: The risk of venous thromboembolism (VTE) is increased 7-fold in patients with cancer than in those without. Low-molecular-weight heparin is the standard treatment for cancer-associated VTE. Direct oral anticoagulants...
9.
Onita T, Ikawa K, Nakamura K, Nishikawa G, Kobayashi I, Ishihara N, et al.
J Clin Pharmacol
. 2020 Dec;
61(6):820-831.
PMID: 33314138
This study aims to define the penetration of ampicillin and sulbactam into prostate tissue, develop a prostatic pharmacokinetic model of each drug, and assess the appropriateness of ampicillin-sulbactam regimens for...
10.
Ishihara N, Nishimura N, Ikawa K, Karino F, Miura K, Tamaki H, et al.
Antibiotics (Basel)
. 2020 Mar;
9(3).
PMID: 32155905
The aim of this study was to develop a population pharmacokinetic model for piperacillin (PIPC)/tazobactam (TAZ) in late elderly patients with pneumonia and to optimize the administration planning by applying...